Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1128442

	registered interest
	date	23/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish the evidence (a) his Department and (b) the Department for International Trade holds on growing a market for prescribed medicinal cannabis.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	257706
	answer	answer is ministerial correction date of answer 10/06/2019 answer text <p><ins class="ministerial"> <p><ins class="ministerial">The Department for International Trade and the Department of Health and Social Care are not specifically collecting data on the growth of the market for cannabis based products for medicinal use in the United Kingdom.</ins></p><p><ins class="ministerial">However, data from the Medicines and Healthcare products Regulatory Agency (MHRA) shows growing numbers of import notifications for medicinal cannabis and the Home Office has received increased numbers of licence applications.</ins></p><p><ins class="ministerial">In addition, UK companies exporting these products and foreign companies looking to invest in the UK have full access to government support, where they have the necessary authorisations from the MHRA and Home Office and a relevant Export Licence.</ins></p></ins></p><p><del class="ministerial">An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</del></p><p><del class="ministerial"><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></del></p><p><del class="ministerial">This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</del></p><p><del class="ministerial">In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</del></p><p><del class="ministerial"><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></del></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/06/2019 13:18:03 question first ministerially corrected 11/06/2019 11:31:21 answering member 4455 label Biography information for Seema Kennedy previous answer version 121340 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1166774

	registered interest
	date	28/10/2019
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what the Government’s policy is on the importation of small amounts of prescribed medical cannabis that have been sourced from abroad.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	6490
	answer	answer is ministerial correction date of answer 05/11/2019 answer text <p><strong><em>It has not proved possible to respond to the hon. Member in the time available before Dissolution.</em></strong></p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 05/11/2019 17:02:31 answering member 4495 label Biography information for Kit Malthouse
	tabling member	4623 label Biography information for Tonia Antoniazzi

942648

	registered interest
	date	16/07/2018
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what guidance his Department has given to the respective health departments in the devolved nations on access to medical cannabis under licence.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	164519
	answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>Advice about clinical applications for medicinal cannabis is available on the gov.uk website, which was publicised at the time of the Expert Panel’s launch. This makes clear that applications must be made by senior clinicians who are on the General Medical Council’s relevant specialist register with an active license to practise.</p><p>The Department for Health and Social Care is working with NHS England and equivalents in the devolved nations to ensure that cannabis based medicinal products are sourced and supplied where a licence is granted. In the longer term, prescribing guidance will be developed following any decision to reschedule these products.</p><p> </p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd question first answered 20/07/2018 13:59:35 answering member 1561 label Biography information for Mr Nick Hurd
	tabling member	4623 label Biography information for Tonia Antoniazzi

942651

	registered interest
	date	16/07/2018
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what discussions he is having with NHS England to ensure that consultants are aware of the licencing process for access to medical cannabis.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	164520
	answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>Advice about clinical applications for medicinal cannabis is available on the gov.uk website, which was publicised at the time of the Expert Panel’s launch. This makes clear that applications must be made by senior clinicians who are on the General Medical Council’s relevant specialist register with an active license to practise.</p><p>The Department for Health and Social Care is working with NHS England and equivalents in the devolved nations to ensure that cannabis based medicinal products are sourced and supplied where a licence is granted. In the longer term, prescribing guidance will be developed following any decision to reschedule these products.</p><p> </p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd question first answered 20/07/2018 14:01:07 answering member 1561 label Biography information for Mr Nick Hurd
	tabling member	4623 label Biography information for Tonia Antoniazzi

1173621

	registered interest
	date	27/01/2020
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what steps her Department is taking to expedite the processes for granting import licences for cannabis-based products for medicinal use.
	tabling member constituency	Inverclyde
	tabling member printed	Ronnie Cowan
	uin	8362
	answer	answer is ministerial correction date of answer 04/02/2020 answer text <p>All applications are considered individually on their merits and with regards to our obligation under International Conventions and Domestic law. Applications for importation of CBPMs are already expedited, where documentation and regulatory approval is provided, in recognition of the need to ensure continuity of the supply of unlicensed medicines. Applications for import licences are normally decided within a few working days.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 04/02/2020 15:54:19 answering member 4495 label Biography information for Kit Malthouse
	tabling member	4465 label Biography information for Ronnie Cowan

1128300

	registered interest
	date	22/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the cost-effectiveness of patients receiving an NHS prescription for wholeplant medical cannabis.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	257476
	answer	answer is ministerial correction date of answer 10/06/2019 answer text <p>An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</p><p>In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</p><p><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 257706 question first answered 10/06/2019 13:18:03 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1128441

	registered interest
	date	23/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the accuracy of evidence base on the cost-effectiveness of medical cannabis.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	257705
	answer	answer is ministerial correction date of answer 10/06/2019 answer text <p>An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</p><p>In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</p><p><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/06/2019 13:23:02 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1131293

	registered interest
	date	11/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many companies are licensed to sell cannabis products to the NHS.
	tabling member constituency	Ross, Skye and Lochaber
	tabling member printed	Ian Blackford
	uin	263171
	answer	answer is ministerial correction date of answer 19/06/2019 answer text <p>Any company meeting the standards for the manufacture of unlicensed medicinal products, can supply cannabis-based products for medicinal use.</p><p> </p><p>Cannabis-based products for medicinal use are Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001, which means that manufacturers, importers and distributors of these products must hold valid Home Office and Medicines and Healthcare products Regulatory Agency (MHRA) licences for the relevant activities which will include possession, supply and production of controlled drugs. Where products are sourced from abroad, importers must obtain an import licence from the Home Office and non-objection to import from the MHRA for each individual import of a controlled drug.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/06/2019 09:39:54 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4390 label Biography information for Ian Blackford

1139188

	registered interest
	date	16/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many UK companies have been issued with a licence to sell cannabis products for the NHS.
	tabling member constituency	Ross, Skye and Lochaber
	tabling member printed	Ian Blackford
	uin	277762
	answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>Any company meeting the standards for the manufacture of unlicensed medicinal products, can supply cannabis-based products for medicinal use.</p><p>Cannabis-based products for medicinal use are Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001, which means that manufacturers, importers and distributors of these products must hold valid Home Office and Medicines and Healthcare products Regulatory Agency (MHRA) licences for the relevant activities which will include possession, supply and production of controlled drugs. Where products are sourced from abroad, importers must obtain an import licence from the Home Office and the MHRA each time they import these products.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/07/2019 15:41:10 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4390 label Biography information for Ian Blackford

927730

	registered interest
	date	20/06/2018
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what estimate he has made of the number of staff his Department will require to process applications for medicinal cannabis; what estimate he has made of the number of such applications that will be made; and if he will make a statement.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	155767
	answer	answer is ministerial correction date of answer 28/06/2018 answer text <p>As I announced on 18 June, the Government is establishing an expert panel of clinicians to advise Ministers on any applications to prescribe cannabis-based medicines. This is intended to ensure that advice to Ministers on licensing in these cases is clinically led, based firmly on medical evidence and as swift as possible. <br>The Chief Medical Officers across the UK have already been actively working together on the panel, and the expert panel will start considering applications within a week. <br>Further details, including who can apply to the panel and what information will be available to guide applicants will be confirmed in due course</p><p>The total number of staff required to process applications is yet to be confirmed.</p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd question first answered 28/06/2018 11:49:54 answering member 1561 label Biography information for Mr Nick Hurd
	tabling member	3930 label Biography information for Caroline Lucas